Clinical Trials Logo

Lymphoma, B-cell clinical trials

View clinical trials related to Lymphoma, B-cell.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06464861 Not yet recruiting - Clinical trials for Mantle Cell Lymphoma (MCL)

Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma

CD19-CARNK/T
Start date: June 10, 2024
Phase: Phase 1
Study type: Interventional

To study the safety and efficacy of cord blood-derived CD19 CAR-NK cells sequential with 7x19 CAR-T in relapse / refractory B cell lymphoma

NCT ID: NCT06458439 Not yet recruiting - Clinical trials for Lymphoma, Non-Hodgkin

Epcoritamab-CAR T Cells for Large B-cell Lymphomas

Start date: July 2024
Phase: Phase 2
Study type: Interventional

This study investigates the feasibility and efficacy of epcoritamab treatment before CAR T cells. This study also investigates if, when patients have residual lymphoma after CAR T cells, epcoritamab can help to effectively treat that lymphoma.

NCT ID: NCT06441097 Not yet recruiting - Clinical trials for Diffuse Large B-Cell Lymphoma

Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

Start date: December 31, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the efficacy and safety of genotype-guided targeted agents in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola RCHP-X) versus Pola RCHP in Chinese patients with previously untreated diffuse large B-cell lymphoma (DLBCL).

NCT ID: NCT06414148 Not yet recruiting - Clinical trials for Relapsed/Refractory Large B-cell Lymphoma

MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma

EpLCART
Start date: May 7, 2024
Phase: Phase 2
Study type: Interventional

This is a Phase II open-label, two-arm randomised non-comparative, multi-centre study to evaluate the efficacy of Epcor-only (Epcoritamab alone) or Epcor-R2 (Epcoritamab, lenalidomide and rituximab) as consolidation post anti-CD19 CAR T-cell therapy for patients that have responded by conventional criteria but who are at high risk of progression by virtue of being Minimal Residual Disease (MRD) positive as determined by a Circulating Tumour DNA (ctDNA) assay.

NCT ID: NCT06412068 Not yet recruiting - Clinical trials for Primary Mediastinal Large B Cell Lymphoma

A Prospective Study: Sintilimab and R-CHOP in PMBCL Treatment

Start date: June 1, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this multi-center, single arm, phase Ⅱ clinical trail is to evaluate the efficacy and toxicity of sintilimab combined with R-CHOP regimen as first-line treatment for primary mediastinal large B-cell Lymphoma (PMBCL)

NCT ID: NCT06365671 Not yet recruiting - Clinical trials for B-NHL, Extranodal, TP53 Alterations, Bulky Mass

CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors

Start date: April 2024
Phase: Phase 2
Study type: Interventional

Clinical trial for the safety and efficacy of CD19 CAR-T following autologous hematopoietic stem cell transplantation (ASCT) for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) with High-Risk Prognostic Factors

NCT ID: NCT06350994 Not yet recruiting - Multiple Myeloma Clinical Trials

Early Assessment of Cardiac Function After Treatment With CAR-T Cells

Cardio CAR-T
Start date: September 2024
Phase:
Study type: Observational

CAR-T cells (Chimeric Antigen Receptor) are a new immunotherapy, based on the genetic modification of autologous T lymphocytes. CAR-T cell therapy is not devoid of complications. Among the most frequent complications are the risk of infection, cytokine release syndrome (CRS) and neurotoxicity. Nevertheless, some authors have reported serious acute cardiac events in a limited number of patients, often contemporaneous with CRS or sepsis, questioning the imputability of CAR-T cells in this heart disease. This study aims to estimate the incidence of a possible early cardiotoxicity associated with CAR-T cells. The main endpoint will be the change in cardiac function (LVEF: left ventricular ejection fraction) assessed by ultrasound between the pre CAR-T assessment and the early post CAR-T ultrasound (D3-D5).

NCT ID: NCT06343311 Not yet recruiting - Lymphoma Clinical Trials

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

STARLIGHT-1
Start date: June 15, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety of an autologous T-cell therapy (EB103) and to determine the Recommended Phase II Dose (RP2D) in adult subjects (≥ 18 years of age) who have relapsed/refractory (R/R) B-cell NHL. The study will include a dose escalation phase followed by an expansion phase.

NCT ID: NCT06318884 Not yet recruiting - Clinical trials for Non-Hodgkin Lymphoma, B-cell

A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma

Start date: April 2024
Phase: Phase 1
Study type: Interventional

This is a Phase I clinical study designed to evaluate the safety, tolerability, and pharmacokinetics, and preliminary efficacy of SCTB35 monotherapy, an bispecific antibody, in patients with relapsed and/or refractory B-cell non-Hodgkin lymphoma.

NCT ID: NCT06314828 Not yet recruiting - Clinical trials for B-cell Non-Hodgkin's Lymphoma

A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL

Start date: May 20, 2024
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label, single-arm study to evaluate tolerability, safety and efficacy of RJMty19 in adult subjects with r/r B-NHL.